Search

Your search keyword '"Cantarella, M. A."' showing total 262 results
Start Over Author "Cantarella, M. A."
262 results on '"Cantarella, M. A."'

8. [18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer

Author

Pasqualetti, F, Panichi, M, Sollini, M, Sainato, A, Galli, L, Morganti, R, Chiacchio, S, Marciano, A, Zanca, R, Mannelli, L, Coraggio, G, Sbrana, A, Cocuzza, P, Montrone, S, Baldaccini, D, Gonnelli, A, Molinari, A, Cantarella, M, Mazzotti, V, Ricci, S, Paiar, F, Erba, P, Pasqualetti F., Panichi M., Sollini M., Sainato A., Galli L., Morganti R., Chiacchio S., Marciano A., Zanca R., Mannelli L., Coraggio G., Sbrana A., Cocuzza P., Montrone S., Baldaccini D., Gonnelli A., Molinari A., Cantarella M., Mazzotti V., Ricci S., Paiar F., Erba P. A., Pasqualetti, F, Panichi, M, Sollini, M, Sainato, A, Galli, L, Morganti, R, Chiacchio, S, Marciano, A, Zanca, R, Mannelli, L, Coraggio, G, Sbrana, A, Cocuzza, P, Montrone, S, Baldaccini, D, Gonnelli, A, Molinari, A, Cantarella, M, Mazzotti, V, Ricci, S, Paiar, F, Erba, P, Pasqualetti F., Panichi M., Sollini M., Sainato A., Galli L., Morganti R., Chiacchio S., Marciano A., Zanca R., Mannelli L., Coraggio G., Sbrana A., Cocuzza P., Montrone S., Baldaccini D., Gonnelli A., Molinari A., Cantarella M., Mazzotti V., Ricci S., Paiar F., and Erba P. A.

Abstract

Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.

Published
2020

10. Stereotactic radiotherapy for oligometastases in the lymph nodes

Author

Pasqualetti, F., Trippa, F., Aristei, C., Borghesi, S., Colosimo, C., Cantarella, M., Mazzola, R., and Ingrosso, G.

Subjects
Oligometastasis, Toxicity, Oncology, Local control, Stereotactic radiotherapy, Hypofractionation, Radiology, Nuclear Medicine and imaging, Bed, Organ motion, Radiosurgery, Lymph node metastases
Abstract

Even though systemic therapy is standard treatment for lymph node metastases, metastasis-directed stereotactic radiotherapy (SRT ) seems to be a valid option in oligometastatic patients with a low disease burden. Positron emission tomography-computed tomography (PET-CT ) is the gold standard for assessing metastases to the lymph nodes; co-registration of PET-CT images and planning CT images are the basis for gross tumor volume (GTV ) delineation. Appropriate techniques are needed to overcome target motion. SRT schedules depend on the irradiation site, target volume and dose constraints to the organs at risk (OARs) of toxicity. Although several fractionation schemes were reported, total doses of 48-60 Gy in 4-8 fractions were proposed for mediastinal lymph node SRT, with the spinal cord, esophagus, heart and proximal bronchial tree being the dose limiting OAR s. Total doses ranged from 30 to 45 Gy, with daily fractions of 7-12 Gy for abdominal lymph nodes, with dose limiting OARs being the liver, kidneys, bowel and bladder. SRT on lymph node metastases is safe; late side effects, particularly severe, are rare.

Published
2021

14. Image-guided stereotactic body radiotherapy in metastatic prostate cancer

Author

Pasqualetti, F, Panichi, M, Sainato, A, Baldaccini, D, Cocuzza, P, Gonnelli, A, Montrone, S, Molinari, A, Barbiero, S, Bruschi, A, Notini, E, Ursino, S, Mazzotti, V, Morganti, R, Coraggio, G, Cantarella, M, Erba, P, Paiar, F, Pasqualetti F., Panichi M., Sainato A., Baldaccini D., Cocuzza P., Gonnelli A., Montrone S., Molinari A., Barbiero S., Bruschi A., Notini E., Ursino S., Mazzotti V., Morganti R., Coraggio G., Cantarella M., Erba P. A., Paiar F., Pasqualetti, F, Panichi, M, Sainato, A, Baldaccini, D, Cocuzza, P, Gonnelli, A, Montrone, S, Molinari, A, Barbiero, S, Bruschi, A, Notini, E, Ursino, S, Mazzotti, V, Morganti, R, Coraggio, G, Cantarella, M, Erba, P, Paiar, F, Pasqualetti F., Panichi M., Sainato A., Baldaccini D., Cocuzza P., Gonnelli A., Montrone S., Molinari A., Barbiero S., Bruschi A., Notini E., Ursino S., Mazzotti V., Morganti R., Coraggio G., Cantarella M., Erba P. A., and Paiar F.

Abstract

Background/Aim: In the last years, the use of Image Guided Stereotactic Radiotherapy (IG-SBRT) in patients with metastatic prostate cancer has increased. In this study, we aimed to assess the role of IG-SBRT in terms of local control and safety in patients with metastatic prostate cancer. Materials and Methods: Primary and secondary endpoints of this prospective observational study were local control and safety related to IG-SBRT. All lesions were treated with 24 Gy as a single fraction or 27 Gy in 3 fractions. After SBRT, Systemic therapies were administered only after the occurrence of more than three synchronous active lesions in oligometastatic patients (patients with less than 4 active synchronous lesions) or new lesions occurrence in patients with more than 3 synchronous lesions. Results: From April 2011 to June 2017, 78 metastatic lesions (32 bone and 46 node) from 51 patients with prostate cancer were treated. After a median follow-up of 18.5 months (range=3-103 months), only 2 lesions (4%) relapsed inside the radiation field. All local recurrences were located on the bone. Estimated 12 and 24 months local control ratios were 98.7 and 97.4%, respectively. Except for one case, toxicity greater than G2 was not recorded. Conclusion: IG-SBRT is safe and can be considered as a valid therapy in patients with metastatic prostate cancer requiring a long-lasting metastases control.

Published
2018

22. EP-1568 Long-term results of [18F] Fluorocholine PET/CT guided SBRT in patients with prostate cancer

Author

Pasqualetti, F., primary, Panichi, M., additional, Cocuzza, P., additional, Gonnelli, A., additional, Baldaccini, D., additional, Molinari, A., additional, Cantarella, M., additional, Mattioni, R., additional, Montrone, S., additional, Cristaudo, A., additional, Marciano, A., additional, Zanca, R., additional, Sollini, M., additional, Sainato, A., additional, Erba, P.A., additional, and Paiar, F., additional

Published
2019
Full Text
View/download PDF

24. Stereotactic body radiotherapy of bone metastases in oligometastatic disease: Prognostic factors of oncologic outcomes

Author

Ursino, S, Montrone, S, Cantarella, M, Menghini, V, Matteucci, F, Mazzotti, V, Fiorica, F, Fedele, D, Erba, P, Morganti, R, Fabrini, M, Caramella, D, Ursino S., Montrone S., Cantarella M., Menghini V., Matteucci F., Mazzotti V., Fiorica F., Fedele D., Erba P., Morganti R., Fabrini M. G., Caramella D., Ursino, S, Montrone, S, Cantarella, M, Menghini, V, Matteucci, F, Mazzotti, V, Fiorica, F, Fedele, D, Erba, P, Morganti, R, Fabrini, M, Caramella, D, Ursino S., Montrone S., Cantarella M., Menghini V., Matteucci F., Mazzotti V., Fiorica F., Fedele D., Erba P., Morganti R., Fabrini M. G., and Caramella D.

Abstract

Background: To evaluate the safety of stereotactic body radiotherapy (SBRT) of bone metastases in oligometastatic disease and to investigate prognostic factors of local control (LC), progression/disease-free survival (PDFS), and overall survival (OS). Methods: Eligibility criteria were number of metastates ≤5, controlled primary tumor without evidence of progression under systemic therapy, exclusion of surgery, and no previous radiotherapy of the lesion of interest. Oligometastatic status was classified into only bone (BOD) and outside bone disease (OBOD), whereas SBRT was delivered to bone lesions using 2 different schedules: 24 Gy/1 fraction or 27 Gy/3 fractions. A positron emission tomography study of the lesion of interest was performed at baseline and at 3 months after SBRT to evaluate metabolic response according to European Organization for Research and Treatment of Cancer (EORTC) criteria. A Cox regression model was used for univariate and multivariate analysis. Results: Between January 2010 and December 2013, 40 patients were enrolled. Only 1 patient experienced severe late toxicity (radiation-related fracture). Local control was longer among responders' than nonresponders' lesions (94.2% and 91.2% versus 63% and 35% at 1 and 2 years, respectively) (p = 0.004; hazard ratio = 9.958). The multivariate analysis of PDFS showed a significant correlation with planning target volume (PTV) size (p = 0.003) and oligometastatic status (p = 0.002). The multivariate analysis of OS confirmed a statistically significant value of the oligometastatic status (p = 0.002) and a significant trend for PTV size (p = 0.065). Conclusions: Stereotactic body radiotherapy is safe with a low incidence of severe toxicity. Positron emission tomography response was a strong prognostic factor of LC whereas BOD status and small PTV size could identify a subset of oligometastatic patients at better prognosis.

Published
2016

30. EP-1129: Perfusion CT in the evaluation of Nodal response after RCT in H&N cancers: a prospective study

Author

Delishaj, D., primary, Ursino, S., additional, Cristaudo, A., additional, Pasqualetti, F., additional, Morganti, R., additional, Matteucci, F., additional, Lombardo, E., additional, Cantarella, M., additional, Orlandi, F., additional, Montrone, S., additional, Baldaccini, D., additional, Gonnelli, A., additional, Molinari, A., additional, Mattioli, R., additional, Calistri, E., additional, Ferrazza, P., additional, Faggioni, L., additional, Caramella, D., additional, and Paiar, F., additional

Published
2018
Full Text
View/download PDF

38. Acetonitrile Biotransformation into Less Toxic Compounds by a Bioprocess Based on the Nitrile Hydratase/Amidase Sequential Enzymatic Reactions

Author

Chuchat, MISS NATCHARI, Pasquarelli, Fabrizia, Spera, Agata, Cantarella, L., and Cantarella, M.

Subjects
nitrile hydratase/amidase, biotransformation of acetonitrile streams, in-situ sequential enzymes, biocatalysts, lcsh:Computer engineering. Computer hardware, batch reactor, acetonitrile biotransformation, batch reactor, UF-membrane reactor, nitrile hydratase/amidase, lcsh:TP155-156, in-situ sequential enzymes, lcsh:TK7885-7895, UF-membrane reactor, lcsh:Chemical engineering, acetonitrile biotransformation, biotransformation of acetonitrile streams, biocatalysts
Abstract

The nitrile hydratase/amidase in-situ sequential enzymes of Microbacterium imperiale CBS 498-74 were used, as biocatalysts, for the biotransformation of acetonitrile streams into less toxic compounds: the corresponding acetamide and acetic acid. This preliminary study aimed to investigate the possible use of resting cells of this strain for pollutant removal. The kinetic parameters, KM and Vmax, evaluated in batch reactor, at 20 °C, and in 50 mM sodium phosphate buffer, at pH 5.0 and 7.0, were at pH 5.0, 60.4 mM (or at pH 7.0, 74.96 mM) and 0.44 µmol min-1 mgDCW-1 (or at pH 7.0, 0.46 µmol min-1 mgDCW-1), respectively. The reactions were unaffected in the whole range of pH, 3.5 till 8.5. Acetonitrile biotransformation, up to 300 mM, into the corresponding acetamide and acetic acid was driven to completeness, at steady state, in Continuous Stirred UF-Membrane Reactor (CSMR). The importance of stirring was also assessed.

Published
2016

39. EP-1282: Clinical and pathological prognostic factors in locally advanced rectal cancer (larc)

Author

Montrone, S., primary, Sainato, A., additional, Morganti, R., additional, Vivaldi, C., additional, Laliscia, C., additional, Manfredi, B., additional, Coraggio, G., additional, Cantarella, M., additional, Musettini, G., additional, Delishaj, D., additional, Lombardo, E., additional, Cristaudo, A., additional, Orlandi, F., additional, Masi, G., additional, Buccianti, P., additional, Falcone, A., additional, Pasqualetti, F., additional, and Paiar, F., additional

Published
2017
Full Text
View/download PDF

40. PO-0665: The role of post-mastectomy radiotherapy (PMRT) and prognostic factors of locoregional recurrence

Author

Delishaj, D., primary, Ursino, S., additional, Mazzotti, V., additional, Fatigante, L.R., additional, Spagnesi, S., additional, Manfredi, B., additional, Cristaudo-, A., additional, Pasqualetti, F., additional, Sainato, A., additional, Laliscia, C., additional, Pnichi, M., additional, Orlandi, F., additional, Matteucci, F., additional, Morganti, R., additional, Lombardo, E., additional, Cantarella, M., additional, Baldaccini, D., additional, Gonnelli, A., additional, Fabrini, M.G., additional, Molinari, A., additional, Roncella, M., additional, Falcone, A., additional, Caramella, D., additional, and Paiar, F., additional

Published
2017
Full Text
View/download PDF

41. PO-0630: The role of mc4r gene polymorphisms in gbm patients treated with concomitant radio-chemotherapy

Author

Cantarella, M., primary, Pasqualetti, F., additional, Gonnelli, A., additional, Orlandi, P., additional, Giuliani, D., additional, Delishaj, D., additional, Montrone, S., additional, Coraggio, G., additional, Lombardo, E., additional, Simeon, V., additional, Di Desiderio, T., additional, Fioravanti, A., additional, Fabrini, M., additional, Danesi, R., additional, Guarini, S., additional, Paiar, F., additional, and Bocci, G., additional

Published
2017
Full Text
View/download PDF

42. EP-1275: Patients with locally advanced rectal cancer (larc): predictive factors of pathological response

Author

Montrone, S., primary, Sainato, A., additional, Morganti, R., additional, Vivaldi, C., additional, Manfredi, B., additional, Laliscia, C., additional, Cantarella, M., additional, Coraggio, G., additional, Musettini, G., additional, Gonnelli, A., additional, Masi, G., additional, Buccianti, P., additional, Pasqualetti, F., additional, and Paiar, F., additional

Published
2017
Full Text
View/download PDF

44. P09.41 Single agent Bevacizumab in recurrent glioblastoma after a second line chemotherapy with Fotemustine. The Italian Association of Neuro Oncology experience

Author

Gonnelli, A., primary, Cantarella, M., additional, Molinari, A., additional, Villani, G., additional, Lombardi, G., additional, Fabrini, M., additional, Pace, A., additional, Fabi, A., additional, Pasqualetti, F., additional, Rudà, R., additional, Soffietti, R., additional, and Paiar, F., additional

Published
2017
Full Text
View/download PDF

46. The role of post-mastectomy radiotherapy (PMRT) and prognostic factors of locoregional recurrence

Author

Delishaj, D., primary, Ursino, S., additional, Mazzotti, V., additional, Spagnesi, S., additional, Fatigante, L.R., additional, Manfredi, B., additional, Cristaudo, A., additional, Pasqualetti, F., additional, Orlandi, F., additional, Morganti, R., additional, Concetta, L., additional, Roncella, M., additional, Cantarella, M., additional, Lombardo, E., additional, Fontana, A., additional, Matteucci, F., additional, Michelotti, A., additional, Fabrini, M.G., additional, Falcone, A., additional, and Paiar, F., additional

Published
2017
Full Text
View/download PDF

47. PO-0756: Choline PET/CT and Stereotactic Body Radiotherapy in oligometastatic prostate cancer patients

Author

Pasqualetti, F., primary, Panichi, M., additional, Sainato, A., additional, Matteucci, F., additional, Derosa, L., additional, Cocuzza, P., additional, Coraggio, G., additional, Ferrazza, P., additional, Montrone, S., additional, Cantarella, M., additional, Delishaj, D., additional, Cristaudo, A., additional, Fabrini, M., additional, Greco, C., additional, and Erba, P., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results